Vontobel Holding Ltd. Acquires 241,440 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Vontobel Holding Ltd. raised its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 412.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 300,000 shares of the biopharmaceutical company’s stock after purchasing an additional 241,440 shares during the quarter. Vontobel Holding Ltd.’s holdings in Sangamo Therapeutics were worth $259,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in shares of Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 1,528,600 shares in the last quarter. Wasatch Advisors LP lifted its position in Sangamo Therapeutics by 62.4% during the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after buying an additional 7,734,400 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after acquiring an additional 192,385 shares during the last quarter. Marshall Wace LLP increased its position in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 207,476 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on SGMO shares. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a research note on Sunday, July 28th. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sangamo Therapeutics currently has an average rating of “Hold” and a consensus price target of $2.67.

Sangamo Therapeutics Price Performance

Shares of NASDAQ SGMO opened at $1.54 on Thursday. The company’s 50 day simple moving average is $0.86 and its 200 day simple moving average is $0.66. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.29 and a fifty-two week high of $1.77. The firm has a market capitalization of $320.66 million, a P/E ratio of -1.12 and a beta of 1.23.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. Sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.